28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
(1) The overall sensitivity of the NINCDS-ADRDA criteria in diagnosing "probable" AD from 56 patients with cortical dementia (AD and FTD) was 0.93. 5 key findings →
Participants: 56 Evidence: low
Full summary, score breakdown and related studies → Original source
An alternative model, the multiple trace theory (MTT), suggests that the capacity of the MTL to recollect episodic memories is of a more permanent nature. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma biomarkers of AD using the automated Lumipulse platform show good diagnostic performance in detecting Alzheimer's pathology in cognitively unimpaired subjects. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cross-sectional cerebrospinal fluid (CSF) levels of tau and amyloid (A) beta (beta) are of diagnostic importance for Alzheimer's disease (AD) and mild cognitive impairment (MCI). 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease CSF biomarkers 42 amino acid long amyloid-β peptide (Aβ1-42), total tau protein (T-tau), and tau protein phosphorylated at threonine 181 (P-tau181) are considered surrogate biomarkers of Alzheimer's disease pathology, and significantly improve diagnostic accuracy. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cerebrospinal fluid (CSF) biomarkers, such as Aβ(42), total-tau and phosphorylated-tau(181) reflect neuropathological changes of Alzheimer's disease (AD). 3 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
CSF susAβ levels are influenced by biological and technical factors, and may represent a marker of Aβ susceptible to lipoprotein-mediated clearance. 1 key finding →
Participants: 69 Evidence: low
Full summary, score breakdown and related studies → Original source
These results indicate that FS (p-tau231 and MMSE) has a strong potential to provide an early distinction between AD and VaD. 4 key findings →
Participants: 198 Evidence: low
Full summary, score breakdown and related studies → Original source
The p-tau181/Aβ42 ratio alone might reliably detect AD pathology in heterogeneous samples of patients suffering from different types of dementia. 1 key finding →
Participants: 526 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is traditionally considered irreversible. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This is the first study showing increased calpain activity and microparticle levels in CSF of AD patients. 3 key findings →
Participants: 64 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma p-tau181 and Centiloid scale alone or in combination with other biomarkers, might predict future cognitive stage transition in non-dementia patients. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
One-hundred-thirthy-three participants, namely 55 A+T+N+ AD, 28 Neurodegenerative disorders (NDD) and 50 controls were enrolled for the study. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The character of central nervous system (CNS) HIV infection and its effects on neuronal integrity vary with evolving systemic infection. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies suggest that subcortical structures, including striatum, are vulnerable to amyloid-β accumulation and other neuropathological features in familial Alzheimer's disease due to autosomal dominant mutations. 5 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common neurodegenerative disease in the older adults. 4 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
We used Illumina Human HT-12 v4 arrays to compare RNA expression of middle temporal gyrus (MTG; BA21) in Alzheimer's disease (AD = 97) and non-demented controls (ND = 98). 4 key findings →
Participants: 938 Evidence: low
Full summary, score breakdown and related studies → Original source
Glial changes are intimately associated with the white matter lesions, and regressive changes in astrocytes and loss of oligodendroglial cells have been reported. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Our results confirm plasma β-amyloid 42 /β-amyloid 40 as a robust biomarker of brain β-amyloid-positivity (area under curve, 0.80-0.87). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Aβ-40 and tau levels were higher and the Aβ-42 level and Aβ-42/Aβ-40 ratio were lower in DS than in the controls (all p < 0.001). 5 key findings →
Participants: 62 Evidence: low
Full summary, score breakdown and related studies → Original source
The poor correlations for Aβ42 in plasma might have several potential explanations, such as the high levels of plasma proteins (compared to CSF), sensitivity to pre-analytical sample handling and specificity, and cross-reactivity of different antibodies. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Overall, our results indicate that β3AR stimulation reverses memory deficits and shifts downward the insoluble Aβ42/Aβ40 ratio in 16-month-old 3xTg-AD mice. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this Chinese population, AD plasma biomarkers vary by age, sex, and APOE genotype. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The blood-brain barrier (BBB) breakdown has been suggested as an early marker for Alzheimer's disease (AD); yet the relationship between BBB breakdown and AD-specific biomarkers based on the amyloid/tau/neurodegeneration framework is not clear. 2 key findings →
Participants: 62 Evidence: low
Full summary, score breakdown and related studies → Original source
Salivary Aβ40, Aβ42, t-tau, and p -tau 181 are commonly employed in Alzheimer's disease (AD) investigations. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →